Skip to main content

Table 1 Clinical findings at study entry in patients with early rheumatoid arthritisa

From: Clinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritis

Parameters Data (N= 50)
Demographics  
   Age, years (range) 52 (30 to 80)
   Sex, females/males 36/14
Smoking history, n (%)  
   Current 8 (16)
   Former 9 (18)
   Never 33 (66)
   Disease duration, months 4 (1 to 12)
Autoantibodies  
   Rheumatoid factor (RF), no. positive (%) 30 (60)
   Anti-CCP 39 (78)
   RF or anti-CCP 42 (84)
Inflammatory indices  
   Erythrocyte sedimentation rate (ESR), mm/h (range) 23 (3 to 98)
   C-reactive protein (CRP), mg/L (range) 7.6 (0.2 to 118)
Disease activity  
   DAS28-ESR 4.7 (1.6 to 8.1)
   Tender joint count (TJC), n (range) 8 (0 to 26)
   Swollen joint count (SJC), n (range) 3 (0 to 23)
   Clinical Disease Activity Index (CDAI) 19.2 (2 to 57.7)
   Health Assessment Questionnaire (HAQ) 0.35 (0 to 2.55)
Medications prior to study entry, n (%)  
   Prednisone 13 (26)
   Nonsteroidal anti-inflammatory drug (NSAID) 30 (60)
   Methotrexate (MTX) 0
   Tumor necrosis factor (TNF) inhibitor 0
  1. aData are expressed as median (interquartile range) values unless otherwise noted. Anti-cyclic citrullinated peptide: anti-CCP; DAS28: Disease Activity Score based on 28-joint count.